Cargando…

The comparable efficacy of denosumab on bone mineral density in rheumatoid arthritis patients with postmenopausal osteoporosis: A retrospective case-control study

Little is known about differences in the therapeutic efficacy of denosumab in subjects with and without rheumatoid arthritis (RA). This study compares the changes in bone mineral density (BMD) between RA patients and controls without RA who had been treated with denosumab for 2 years for postmenopau...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Seong-Kyu, Kim, Ji-Won, Lee, Hwajeong, Park, Sung-Hoon, Choe, Jung-Yoon, Kim, Boyoung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313284/
https://www.ncbi.nlm.nih.gov/pubmed/37390268
http://dx.doi.org/10.1097/MD.0000000000034219
_version_ 1785067092853129216
author Kim, Seong-Kyu
Kim, Ji-Won
Lee, Hwajeong
Park, Sung-Hoon
Choe, Jung-Yoon
Kim, Boyoung
author_facet Kim, Seong-Kyu
Kim, Ji-Won
Lee, Hwajeong
Park, Sung-Hoon
Choe, Jung-Yoon
Kim, Boyoung
author_sort Kim, Seong-Kyu
collection PubMed
description Little is known about differences in the therapeutic efficacy of denosumab in subjects with and without rheumatoid arthritis (RA). This study compares the changes in bone mineral density (BMD) between RA patients and controls without RA who had been treated with denosumab for 2 years for postmenopausal osteoporosis. A total of 82 RA patients and 64 controls were enrolled, who were refractory to selective estrogen receptor modulators (SERMs) or bisphosphonates and completed the treatment of denosumab 60 mg for 2 years. The efficacy of denosumab in RA patients and controls was assessed using areal BMD (aBMD) and T-score of the lumbar spine, femur neck, and total hip. A general linear model with repeated measures analysis of variance was used to determine differences in aBMD and T-score between 2 study groups. No significant differences in percent changes in aBMD and T-scores by denosumab treatment for 2 years at the lumbar spine, femur neck, and total hip were evident between RA patients and controls (P > .05 of all), except T-score of the total hip (P = .034). Denosumab treatment equally increased aBMD at the lumbar spine and T-scores at the lumbar spine and total hip between RA patients and controls without statistical differences, but RA patients showed less improvement in aBMD at the femur neck (p(time*group) = 0.032) and T-scores at the femur neck and total hip than controls (p(time*group) = 0.004 of both). Changes in aBMD and T-scores after denosumab treatment in RA patients were not affected by previous use of bisphosphonates or SERMs. Differences of T-score at the femur neck among previous bisphosphonate users and aBMD and T-score at the femur neck and T-scores at the total hip were evident. This study revealed that 2 years of denosumab treatment in female RA patients achieved comparable efficacy on BMD to controls at the lumbar spine, but showed somewhat insufficient improvement at the femur neck and total hip.
format Online
Article
Text
id pubmed-10313284
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-103132842023-07-01 The comparable efficacy of denosumab on bone mineral density in rheumatoid arthritis patients with postmenopausal osteoporosis: A retrospective case-control study Kim, Seong-Kyu Kim, Ji-Won Lee, Hwajeong Park, Sung-Hoon Choe, Jung-Yoon Kim, Boyoung Medicine (Baltimore) 6900 Little is known about differences in the therapeutic efficacy of denosumab in subjects with and without rheumatoid arthritis (RA). This study compares the changes in bone mineral density (BMD) between RA patients and controls without RA who had been treated with denosumab for 2 years for postmenopausal osteoporosis. A total of 82 RA patients and 64 controls were enrolled, who were refractory to selective estrogen receptor modulators (SERMs) or bisphosphonates and completed the treatment of denosumab 60 mg for 2 years. The efficacy of denosumab in RA patients and controls was assessed using areal BMD (aBMD) and T-score of the lumbar spine, femur neck, and total hip. A general linear model with repeated measures analysis of variance was used to determine differences in aBMD and T-score between 2 study groups. No significant differences in percent changes in aBMD and T-scores by denosumab treatment for 2 years at the lumbar spine, femur neck, and total hip were evident between RA patients and controls (P > .05 of all), except T-score of the total hip (P = .034). Denosumab treatment equally increased aBMD at the lumbar spine and T-scores at the lumbar spine and total hip between RA patients and controls without statistical differences, but RA patients showed less improvement in aBMD at the femur neck (p(time*group) = 0.032) and T-scores at the femur neck and total hip than controls (p(time*group) = 0.004 of both). Changes in aBMD and T-scores after denosumab treatment in RA patients were not affected by previous use of bisphosphonates or SERMs. Differences of T-score at the femur neck among previous bisphosphonate users and aBMD and T-score at the femur neck and T-scores at the total hip were evident. This study revealed that 2 years of denosumab treatment in female RA patients achieved comparable efficacy on BMD to controls at the lumbar spine, but showed somewhat insufficient improvement at the femur neck and total hip. Lippincott Williams & Wilkins 2023-06-30 /pmc/articles/PMC10313284/ /pubmed/37390268 http://dx.doi.org/10.1097/MD.0000000000034219 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 6900
Kim, Seong-Kyu
Kim, Ji-Won
Lee, Hwajeong
Park, Sung-Hoon
Choe, Jung-Yoon
Kim, Boyoung
The comparable efficacy of denosumab on bone mineral density in rheumatoid arthritis patients with postmenopausal osteoporosis: A retrospective case-control study
title The comparable efficacy of denosumab on bone mineral density in rheumatoid arthritis patients with postmenopausal osteoporosis: A retrospective case-control study
title_full The comparable efficacy of denosumab on bone mineral density in rheumatoid arthritis patients with postmenopausal osteoporosis: A retrospective case-control study
title_fullStr The comparable efficacy of denosumab on bone mineral density in rheumatoid arthritis patients with postmenopausal osteoporosis: A retrospective case-control study
title_full_unstemmed The comparable efficacy of denosumab on bone mineral density in rheumatoid arthritis patients with postmenopausal osteoporosis: A retrospective case-control study
title_short The comparable efficacy of denosumab on bone mineral density in rheumatoid arthritis patients with postmenopausal osteoporosis: A retrospective case-control study
title_sort comparable efficacy of denosumab on bone mineral density in rheumatoid arthritis patients with postmenopausal osteoporosis: a retrospective case-control study
topic 6900
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313284/
https://www.ncbi.nlm.nih.gov/pubmed/37390268
http://dx.doi.org/10.1097/MD.0000000000034219
work_keys_str_mv AT kimseongkyu thecomparableefficacyofdenosumabonbonemineraldensityinrheumatoidarthritispatientswithpostmenopausalosteoporosisaretrospectivecasecontrolstudy
AT kimjiwon thecomparableefficacyofdenosumabonbonemineraldensityinrheumatoidarthritispatientswithpostmenopausalosteoporosisaretrospectivecasecontrolstudy
AT leehwajeong thecomparableefficacyofdenosumabonbonemineraldensityinrheumatoidarthritispatientswithpostmenopausalosteoporosisaretrospectivecasecontrolstudy
AT parksunghoon thecomparableefficacyofdenosumabonbonemineraldensityinrheumatoidarthritispatientswithpostmenopausalosteoporosisaretrospectivecasecontrolstudy
AT choejungyoon thecomparableefficacyofdenosumabonbonemineraldensityinrheumatoidarthritispatientswithpostmenopausalosteoporosisaretrospectivecasecontrolstudy
AT kimboyoung thecomparableefficacyofdenosumabonbonemineraldensityinrheumatoidarthritispatientswithpostmenopausalosteoporosisaretrospectivecasecontrolstudy
AT kimseongkyu comparableefficacyofdenosumabonbonemineraldensityinrheumatoidarthritispatientswithpostmenopausalosteoporosisaretrospectivecasecontrolstudy
AT kimjiwon comparableefficacyofdenosumabonbonemineraldensityinrheumatoidarthritispatientswithpostmenopausalosteoporosisaretrospectivecasecontrolstudy
AT leehwajeong comparableefficacyofdenosumabonbonemineraldensityinrheumatoidarthritispatientswithpostmenopausalosteoporosisaretrospectivecasecontrolstudy
AT parksunghoon comparableefficacyofdenosumabonbonemineraldensityinrheumatoidarthritispatientswithpostmenopausalosteoporosisaretrospectivecasecontrolstudy
AT choejungyoon comparableefficacyofdenosumabonbonemineraldensityinrheumatoidarthritispatientswithpostmenopausalosteoporosisaretrospectivecasecontrolstudy
AT kimboyoung comparableefficacyofdenosumabonbonemineraldensityinrheumatoidarthritispatientswithpostmenopausalosteoporosisaretrospectivecasecontrolstudy